{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T03:22:07Z","timestamp":1775445727824,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Samsung Bioepis"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s12325-024-02937-3","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:02:27Z","timestamp":1720443747000},"page":"3426-3436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Usability of the SB11 Pre-filled Syringe (PFS) in Patients with Retinal Diseases"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct06176963","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yujin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Oleksy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Wyl\u0119ga\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Orski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"9","key":"2937_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29583","volume":"14","author":"H Vyawahare","year":"2022","unstructured":"Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14(9):e29583. https:\/\/doi.org\/10.7759\/cureus.29583.","journal-title":"Cureus"},{"issue":"3","key":"2937_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/1573399811666150615151324","volume":"17","author":"C Campa","year":"2016","unstructured":"Campa C, Alivernini G, Bolletta E, Parodi MB, Perri P. Anti-VEGF therapy for retinal vein occlusions. Curr Drug Targets. 2016;17(3):328\u201336. https:\/\/doi.org\/10.2174\/1573399811666150615151324.","journal-title":"Curr Drug Targets"},{"issue":"4","key":"2937_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","volume":"120","author":"PA Campochiaro","year":"2013","unstructured":"Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120(4):795\u2013802. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.032.","journal-title":"Ophthalmology"},{"issue":"4","key":"2937_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","volume":"27","author":"JS Penn","year":"2008","unstructured":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331\u201371. https:\/\/doi.org\/10.1016\/j.preteyeres.2008.05.001.","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"2937_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41433-021-01766-w","volume":"36","author":"F Ghanchi","year":"2022","unstructured":"Ghanchi F, Bourne R, Downes SM, et al. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma. Eye (Lond). 2022;36(6):1154\u201367. https:\/\/doi.org\/10.1038\/s41433-021-01766-w.","journal-title":"Eye (Lond)"},{"issue":"9","key":"2937_CR6","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144\u201367. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2937_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1600-0420.2007.00979.x","volume":"85","author":"UM Schmidt-Erfurth","year":"2007","unstructured":"Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85(5):486\u201394. https:\/\/doi.org\/10.1111\/j.1600-0420.2007.00979.x.","journal-title":"Acta Ophthalmol Scand"},{"issue":"8","key":"2937_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","volume":"26","author":"N Ferrara","year":"2006","unstructured":"Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859\u201370. https:\/\/doi.org\/10.1097\/01.iae.0000242842.14624.e7.","journal-title":"Retina"},{"key":"2937_CR9","unstructured":"United States Food and Drug Administration (US FDA). LUCENTIS (ranibizumab injection) - Highlights of Prescribing Information. 2006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125156s128lbl.pdf. Accessed Feb 28 2024."},{"key":"2937_CR10","unstructured":"European Medicines Agency (EMA). Lucentis: EPAR - Product information. 2007. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lucentis-epar-product-information_en.pdf. Accessed Feb 29 2024."},{"key":"2937_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/OPTH.S169044","volume":"13","author":"TM Sassalos","year":"2019","unstructured":"Sassalos TM, Paulus YM. Prefilled syringes for intravitreal drug delivery. Clin Ophthalmol. 2019;13:701\u20136. https:\/\/doi.org\/10.2147\/OPTH.S169044.","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"2937_CR12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","volume":"42","author":"PK Kaiser","year":"2022","unstructured":"Kaiser PK, Schmitz-Valckenberg MS, Holz FG. Anti-vascular endothelial growth factor biosimilars in ophthalmology. Retina. 2022;42(12):2243\u201350. https:\/\/doi.org\/10.1097\/IAE.0000000000003626.","journal-title":"Retina"},{"key":"2937_CR13","unstructured":"United States Food and Drug Administration (US FDA). Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https:\/\/www.fda.gov\/media\/82647\/download\u00a0Accessed Feb 28 2024."},{"key":"2937_CR14","unstructured":"European Medicines Agency (EMA). Guideline on similar biological medicinal products. 2014. https:\/\/www.ema.europa.eu\/system\/files\/documents\/scientific-guideline\/wc500176768_en.pdf. Accessed Apr 23 2024."},{"issue":"7","key":"2937_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","volume":"141","author":"SJ Woo","year":"2023","unstructured":"Woo SJ, Bradvica M, Vajas A, et al. Efficacy and safety of the aflibercept biosimilar SB15 in neovascular age-related macular degeneration: a phase\u00a03 randomized clinical trial. JAMA Ophthalmol. 2023;141(7):668\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2260.","journal-title":"JAMA Ophthalmol"},{"key":"2937_CR16","unstructured":"United States Food and Drug Administration (US FDA). BYOOVIZ (ranibizumab-nuna) US prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761202s006lbl.pdf. Accessed Feb 29 2024."},{"key":"2937_CR17","unstructured":"European Medicines Agency (EMA). Byooviz: EPAR - Product information. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byooviz-epar-product-information_en.pdf. Accessed Feb 29 2024."},{"issue":"2","key":"2937_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40123-022-00453-7","volume":"11","author":"E Kim","year":"2022","unstructured":"Kim E, Han J, Chae Y, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB11, as Lucentis (\u00ae) (ranibizumab) biosimilar. Ophthalmol Ther. 2022;11(2):639\u201352. https:\/\/doi.org\/10.1007\/s40123-022-00453-7.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"2937_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaophthalmol.2020.5053","volume":"139","author":"SJ Woo","year":"2021","unstructured":"Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139(1):68\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5053.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"2937_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","volume":"107","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Veith M, Hamouz J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase\u00a0III randomised clinical trial outcomes. Br J Ophthalmol. 2023;107(3):384\u201391. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319637.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2937_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","volume":"141","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Kim T, Oh I, Russo P, Kim MY, Woo SJ. Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase\u00a03 randomized clinical trial. JAMA Ophthalmol. 2023;141(2):117\u201327. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.5403.","journal-title":"JAMA Ophthalmol"},{"key":"2937_CR22","unstructured":"United States Food and Drug Administration (US FDA). BLA 761202\/S-006 Supplement Approval. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/761202Orig1s006ltr.pdf. Accessed Apr 02 2024."},{"key":"2937_CR23","unstructured":"United States Food and Drug Administration (US FDA). Human factors studies and related clinical study considerations in combination product design and development. 2016. Accessed Feb 29 2024."},{"issue":"5","key":"2937_CR24","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/jps.23945","volume":"103","author":"K Yoshino","year":"2014","unstructured":"Yoshino K, Nakamura K, Yamashita A, et al. Functional evaluation and characterization of a newly developed silicone oil-free prefillable syringe system. J Pharm Sci. 2014;103(5):1520\u20138. https:\/\/doi.org\/10.1002\/jps.23945.","journal-title":"J Pharm Sci"},{"key":"2937_CR25","first-page":"10","volume":"55","author":"W Dierick","year":"2015","unstructured":"Dierick W, Yoshino K. Using prefillable syringes for biopharmaceuticals: development & challenges. OnDrug Deliv. 2015;55:10\u20136.","journal-title":"OnDrug Deliv"},{"key":"2937_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","volume":"199","author":"PP Storey","year":"2019","unstructured":"Storey PP, Tauqeer Z, Yonekawa Y, et al. The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab. Am J Ophthalmol. 2019;199:200\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2018.11.023.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2937_CR27","first-page":"A5214","volume":"63","author":"Y Subhi","year":"2016","unstructured":"Subhi Y, Kjer B, Munch IC. Prefilled syringes for intravitreal injection reduce preparation time. Dan Med J. 2016;63(4):A5214.","journal-title":"Dan Med J"},{"issue":"4","key":"2937_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4103\/2230-973X.93004","volume":"1","author":"S Makwana","year":"2011","unstructured":"Makwana S, Basu B, Makasana Y, Dharamsi A. Prefilled syringes: an innovation in parenteral packaging. Int J Pharm Investig. 2011;1(4):200\u20136. https:\/\/doi.org\/10.4103\/2230-973X.93004.","journal-title":"Int J Pharm Investig"},{"issue":"8","key":"2937_CR29","doi-asserted-by":"publisher","first-page":"e1366","DOI":"10.1111\/aos.14838","volume":"99","author":"GB Melo","year":"2021","unstructured":"Melo GB, da Cruz NFS, do Monte Agra LL, et al. Silicone oil-free syringes, siliconized syringes and needles: quantitative assessment of silicone oil release with drugs used for intravitreal injection. Acta Ophthalmol. 2021;99(8):e1366\u201374. https:\/\/doi.org\/10.1111\/aos.14838.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"2937_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5301\/ejo.5000629","volume":"25","author":"E Souied","year":"2015","unstructured":"Souied E, Nghiem-Buffet S, Leteneux C, et al. Ranibizumab prefilled syringes: benefits of reduced syringe preparation times and less complex preparation procedures. Eur J Ophthalmol. 2015;25(6):529\u201334. https:\/\/doi.org\/10.5301\/ejo.5000629.","journal-title":"Eur J Ophthalmol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02937-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02937-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02937-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T19:14:09Z","timestamp":1721675649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02937-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2937"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02937-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"2 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yujin Lee, Jiwon Lee, and Sunji Kim are employees of Samsung Bioepis Co., Ltd. Edward Wyl\u0119ga\u0142a obtained honoraria\u00a0for lectures from Bayer, Roche, Alfa Sigma, Allergan, Zeiss, and Thea, and is part\u00a0of the advisory board of Allergan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in compliance with International Council for Harmonization and Good Clinical Practice guidelines and the Declaration of Helsinki. Informed consent was obtained from each patient before entering the study. The study and clinical study protocol, informed consent forms (ICFs), and other applicable documents were reviewed and approved by an independent ethics committee (IEC) or Institutional Review Board (IRB) for each study center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}